Zura Bio Limited (NASDAQ:ZURA) Receives Consensus Recommendation of "Buy" from Brokerages

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has received an average recommendation of "Buy" from the eight brokerages that are covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $14.33.

A number of research analysts have recently weighed in on ZURA shares. Oppenheimer cut their price target on shares of Zura Bio from $19.00 to $17.00 and set an "outperform" rating on the stock in a report on Friday, May 9th. HC Wainwright restated a "buy" rating on shares of Zura Bio in a report on Thursday, April 3rd. Guggenheim restated a "buy" rating and set a $15.00 price target on shares of Zura Bio in a report on Wednesday, March 26th. Finally, Chardan Capital cut their price target on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, March 26th.

Zura Bio Trading Down 2.0%

ZURA stock traded down $0.02 during midday trading on Friday, reaching $1.00. The company had a trading volume of 565,550 shares, compared to its average volume of 411,154. Zura Bio has a 1 year low of $0.97 and a 1 year high of $5.56. The company has a market capitalization of $68.38 million, a P/E ratio of -1.43 and a beta of 0.05. The company has a 50 day moving average of $1.25 and a two-hundred day moving average of $1.82.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). On average, sell-side analysts anticipate that Zura Bio will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. ADAR1 Capital Management LLC grew its stake in Zura Bio by 34.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company's stock valued at $3,614,000 after buying an additional 723,933 shares during the last quarter. JPMorgan Chase & Co. grew its position in Zura Bio by 12,060.8% in the 4th quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company's stock worth $6,583,000 after purchasing an additional 2,611,532 shares during the last quarter. Allostery Investments LP grew its position in Zura Bio by 44.2% in the 1st quarter. Allostery Investments LP now owns 2,329,384 shares of the company's stock worth $3,005,000 after purchasing an additional 714,258 shares during the last quarter. Armistice Capital LLC grew its position in Zura Bio by 2.4% in the 1st quarter. Armistice Capital LLC now owns 1,536,000 shares of the company's stock worth $1,981,000 after purchasing an additional 36,000 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Zura Bio by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 955,426 shares of the company's stock worth $2,389,000 after purchasing an additional 42,801 shares during the last quarter. 61.14% of the stock is currently owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.